Metabolomics and serum pharmacochemistry revealed the preventive mechanism of Gushudan in kidney‐yang‐deficiency‐syndrome rats

Abstract Kidney‐yang‐deficiency‐syndrome (KYDS) is a metabolic disease caused by neuroendocrine disorder. Gushudan (GSD) is a traditional Chinese medicine prescription with the effect of nourishing kidney and strengthening bones. In this study, the mechanism of preventive effect of GSD on KYDS was explored by integrating metabolomics and serum pharmacochemistry. Reversed‐phase/hydrophilic interaction chromatography–ultra‐high‐performance liquid chromatography–Quadrupole‐Orbitrap high‐resolution mass spectrometry (RP/HILIC–UHPLC–Q‐Orbitrap HRMS)–based serum metabolomics indicated metabolic disturbances of KYDS rats, and 50 potential biomarkers including l ‐threonine, succinic acid and phytosphingosine were obtained, which were mainly involved in alanine, aspartate and glutamate metabolism, citrate cycle (tricarboxylic acid cycle) and glycerophospholipid metabolism, among others. Serum pharmacochemistry identified 29 prototypical ingredients and 9 metabolites of GSD after administration, such as icaritin and xanthotoxol. The combination of 10 serum migration ingredients in GSD, including icaritin and osthole, with 7 important targets, including AKT serine/threonine kinase 1 (AKT1) and MAPK14, was found to be key for GSD to prevent KYDS in the network pharmacology study. This study provided a new idea for the research of pathogenesis of diseases and the pharmacodynamic mechanism of traditional Chinese medicine.